Grossman - Figure 23
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer 2016
FIG. 23: Other organizations have published opinion concerning this issue of neoadjuvant chemotherapy. This Figure shows relevant recommendations from the European Association of Urology (EAU) guidelines for 2016.[10] According to the EAU, "neoadjuvant chemotherapy should be offered for T2 to T4a clinical N0M0 bladder cancer, and cisplatin-based combination therapy should always be used. Do not offer neoadjuvant chemotherapy to patients who are ineligible for cisplatin-based combination chemotherapy." These recommendations have a strength value of Grade A, so they represent strong recommendations for how to use neoadjuvant therapy.
References
Witjes JA, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71:462–75 http://dx.doi.org/10.1016/j.eururo.2016.06.020
